BOSTON, Aug. 18, 2025 /PRNewswire/ — Intrinsic Therapeutics, Inc., a medical technology company committed to redefining the standard of care for lumbar discectomy patients with large annular defects by reducing reoperations for reherniations by 81%* with its Barricaid Annular Closure Device, announced today the appointment of industry veterans Mike Lytle and Dave Decker as Vice President of Sales, West and Vice President of Sales, East, respectively. Together, Mike and Dave bring more than 60 years of combined experience in spine and orthopedics, along with decades of trusted relationships with surgeons and distributors across the spine community.
Keith Valentine, President and CEO of Intrinsic, said: “Mike and Dave are proven leaders and successful team builders, each with a track record of driving sales growth across multiple high-performing spine implant companies. Their appointment marks an important step forward in our mission to end needless suffering for high-risk discectomy patients. Having worked alongside them for nearly two decades, I know firsthand their professionalism, integrity, and ability to deliver results through a culture of accountability. With their leadership, we are poised to reach more patients, empower more surgeons, and make our vision a reality.”
Dave Decker brings more than 30 years of experience in spine and orthopedics. Most recently, he served as AVP for SeaSpine/Orthofix, where his area ranked as a top-performing region for three consecutive years. Previously, he spent 11 years as Area Sales Director at NuVasive, where he was repeatedly recognized as a top area leader. “Barricaid represents a major advancement in the treatment of disc herniation, enabling us to meet patient needs like never before,” said Decker. “By redefining the standard of care, we can transform the lives of countless patients affected by this condition.”
Mike Lytle has more than 30 years of medical device experience, including 17 years in spine. He spent over a decade as AVP at Orthofix/SeaSpine, leading one of the company’s top-producing regions five times. Before that, he served six years as Senior Sales Director at NuVasive, earning multiple Chairman’s Club awards. Reflecting on his new role, Lytle shared: “Having personally experienced complications from a failed multilevel discectomy, I am deeply passionate about Intrinsic’s mission. Alongside our surgeon partners, we have an obligation to ensure that every qualified patient has access to Barricaid so they can avoid the challenges I faced and live healthier lives.”
About Barricaid
Barricaid is a proprietary technology designed to prevent reherniation and reoperation in patients with large annular defects following lumbar discectomy surgery. Barricaid has been implanted in over 12,000 patients and is supported by clinical studies across eight distinct patient populations, including two randomized controlled trials and six single-arm studies. A multicenter, Level I RCT demonstrating superior outcomes to discectomy alone was published in JAMA with five-year follow-up results.
*Some studies are outside FDA indications. Values at a minimum of 1-year post-op. Minimum study size: 20 Barricaid subjects.
Barricaid is a registered trademark of Intrinsic Therapeutics, Inc.
SOURCE Intrinsic Therapeutics, Inc.